Itolizumab for the Treatment of COVID 19 BIOCON

BIOCON is an Indian  innovation Biopharmaceutical company in Bangalore. The company manufactures APIs that are sold in over 120 countries across the globe. This company mainly manufacures the novel biologics and biosimilar products.

Recently it gets DCGI ( Drug Controller General of India ) approval for the use of ITOLIZUMAB for the treatment of COVID 19. Itolizumab is the first novel biologic therapy to be approved in the world for treating against COVID 19 .

BIOCON said it had received approval on Saturday (July 11)f the DGCI for the treatment of moderate to severe COVID 19 patients. The company received approval to market Itolizumab injection 25 mg/ml solution for emergency use for Severe Acute Respiratory Distress Syndrome patients due to COVID 19.

The drug will be manufactured as intravenous injection .The approval is based on the results from controlled Clinical Trial at multiple Hospitals in MUMBAI and NEW DELHI, BIOCON said.

"As an innovation - biopharmacuetical company ,  I am proud of the successful results of the PIVOTAL STUDY we conducted with our novel immuno modulating anti CD6 monoclonal antibody, ITOLIZUMAB, which has prooved to be an efficacious in the treatment of COVID 19 , BIOCON Executive Chairperson Kiran Mazumdar Shaw said."

In this positions INDIA is the leading global innovators in their effort to overcome the COVID 19 pandemic .

#smartpharmainfo.blogspot.com